TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
Jul 2020 |
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. |
Jan 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
Jun 2020 |
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
Apr 2023 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
Therapy-related myelodysplastic syndromes in the genomics era |
Jun 2023 |
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS |
Jun 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
Therapy for lower-risk MDS |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
Apr 2023 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
Dec 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |